1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CACancer J Clin, 2016, 66:115-132.
[2]
2. Paez JG, Janne PA, Lee JC, et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science, 2004, 304:1497-1500.
[3]
3. Lynch TJ, Bell DW, Scrdella R, et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib.N Engl J Med, 2004, 350:2129-2139.
5. Han SW, Kim TY, Jeon YK, et al.Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.Clin Cancer Res, 2006, 12:2538-2544.
[6]
6. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.Clin Cancer Res, 2007, 13:2890-2896.
[7]
7. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer:a meta-analysis of 22 studies. Lung Cancer, 2010, 69:272-278.
[8]
8. Marks JL, Broderock S, Zhou Q, et al.Prognostic and therapeutic implications of EGFR and KRAS mutations in respected lung adenocarcinoma.J Thorac Oncol, 2008, 3:111-116.
[9]
9. Wu CC, Hsu HY, Liu HP, et al.Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.Cancer, 2008, 113:3199-3208.
16. Wu S, Zhu Z, He J, et al.A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples.Clin Chem Lab Med, 2010, 48:1103-1106.
